Anlotinib improves overall survival in relapsed SCLC
Results of ALTER 1202 reveal survival benefit for anlotinib third-line in small-cell lung cancer
Cediranib–olaparib combination is effective regardless of disease mutations
Results from the BAROCCO trial may help define the optimum treatment schedule for an antiangiogenic–PARP inhibitor combination in recurrent, platinum-resistant ovarian cancer
Not just for girls, so who else should be vaccinated for HPV?
Extending an HPV vaccination programme to include boys aged 12–14 years could help reduce the incidence of these infections
From research bench to the patient’s bedside
ESMO Congress 2019 held in Barcelona, Spain, from 27 September to 1 October 2019
Adding FOLFIRINOX to nab-PG may improve outcomes in pancreatic cancer
Results from the phase II NEOLAP study presented at ESMO 2019